Pfizer Names Cecile Guegan CFO, Sets $1.3 Million Base Salary
Pfizer's board has named Cecile Guegan chief financial officer and executive vice president, removing the interim tag she has carried since August, the drugmaker said in an 8-K filed Tuesday. The appointment took effect Nov. 1, 2026.
Guegan, 55, had served as interim CFO since Aug. 16, 2026. The board elected her unanimously, according to the filing.
What she'll be paid
Pfizer's compensation committee approved an annual base salary of $1,300,000 for Guegan and an annual target cash incentive of $1,300,000, equal to 100% of her base salary, the 8-K said. The incentive will be determined based on salary paid during the year.
Inside the finance chief's remit
Guegan will oversee all of Pfizer's corporate finance functions, including audit, treasury, investor relations, tax, insurance, operations planning and analysis, corporate controllership, and business finance and analytics, according to the press release filed with the 8-K.
She has more than 25 years of finance leadership in the pharmaceutical industry and joined Pfizer through its 2009 acquisition of Wyeth, the filing said. Before taking the interim role, she was senior vice president of finance for Pfizer's Global Biopharmaceuticals business, a post she held since 2022.
What Bourla and Guegan said
Chairman and CEO Albert Bourla called Guegan "an exceptional finance leader who knows our company and industry deeply."
"My focus remains on executing a disciplined approach to capital allocation while making targeted investments today to drive revenue growth later in the decade and beyond," Guegan said in the release.
By the numbers
- Effective date: Nov. 1, 2026
- Interim CFO since: Aug. 16, 2026
- Base salary: $1,300,000
- Target cash incentive: $1,300,000 (100% of salary)
- Pharmaceutical finance experience: more than 25 years
Sources
- Pfizer Inc. Form 8-K and press release on the appointment of Cecile Guegan as Chief Financial Officer, filed Nov. 3, 2026 (accession 0000078003-26-000132)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.